Free Trial
NASDAQ:ATRA

Atara Biotherapeutics Q4 2024 Earnings Report

Atara Biotherapeutics logo
$7.42 +0.10 (+1.37%)
Closing price 04/28/2025 04:00 PM Eastern
Extended Trading
$7.40 -0.03 (-0.34%)
As of 04/28/2025 04:06 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atara Biotherapeutics EPS Results

Actual EPS
-$1.19
Consensus EPS
-$3.82
Beat/Miss
Beat by +$2.63
One Year Ago EPS
N/A

Atara Biotherapeutics Revenue Results

Actual Revenue
$32.75 million
Expected Revenue
$20.58 million
Beat/Miss
Beat by +$12.17 million
YoY Revenue Growth
N/A

Atara Biotherapeutics Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Friday, March 7, 2025
Conference Call Time
9:30AM ET

Upcoming Earnings

Atara Biotherapeutics' Q1 2025 earnings is scheduled for Thursday, May 8, 2025, with a conference call scheduled on Tuesday, May 6, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Atara Biotherapeutics Earnings Headlines

Atara Biotherapeutics (ATRA) Receives a Buy from TD Cowen
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold.
Atara Biotherapeutics reports Q4 EPS ($1.19) vs. ($14.00) last year
See More Atara Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atara Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atara Biotherapeutics and other key companies, straight to your email.

About Atara Biotherapeutics

Atara Biotherapeutics (NASDAQ:ATRA) engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

View Atara Biotherapeutics Profile

More Earnings Resources from MarketBeat